Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1 / Phase 2NCT05490472
Official study title

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Study summary

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedJAB-2485 (Aurora A inhibitor) and JAB-2485 (Aurora A inhibitor)

The study team can explain what participation involves.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 9, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?8 U.S. locations

Locations may change over time.

Who runs it?Jacobio Pharmaceuticals Co., Ltd.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Jacobio Pharmaceuticals Co., Ltd.
Interventions being studied
Drug: JAB-2485 (Aurora A inhibitor); Drug: JAB-2485 (Aurora A inhibitor)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Small cell lung cancer (SCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Must be able to provide an archived tumor sample
  • Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor
  • Dose Expansion phase cohorts must meet specific expression or gene mutation where indicated
  • Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition
  • Must have at least 1 measurable lesion per RECIST v1.1
  • Must have adequate organ functions
  • Must be able to swallow and retain orally administered medication
Reasons someone may not be able to joinExclusion criteria
  • Has central nervous system (CNS) metastases or carcinomatous meningitis, except if CNS metastases treated and no evidence of radiographic progression or hemorrhage for at least 28 days
  • Active infection requiring systemic treatment within 7 days
  • Active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV
  • Any severe and/or uncontrolled medical conditions
  • left ventricular ejection fraction (LVEF) ≤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
  • QT interval using Fridericia's formula (QTcF) interval \>470 msec
  • Experiencing unresolved CTCAE 5.0 Grade \>1 toxicities
  • Clinically significant eye disorders

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Henry Ford Health SystemDetroit, Michigan
  • Washington UniversitySt Louis, Missouri
  • Mary Crowley Cancer ResearchDallas, Texas
  • University of Utah Huntsman Cancer InstituteSalt Lake City, Utah
  • Cancer Hospital Chinese Academy of Medical SciencesBeijing, Beijing Municipality
  • Peking University Third HospitalBeijing, Beijing Municipality
  • Jilin Cancer HospitalChangchun, Jilin
  • Shandong Cancer HospitalJinan, Shandong

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 9, 2026. Always confirm current availability with the study team.

View original record ↗